-
Mashup Score: 0Early palliative care ‘did not show a benefit’ for patients undergoing cancer surgery - 11 month(s) ago
Palliative care specialist services provided around the time of cancer surgery with curative intent failed to significantly improve patient outcomes, results of a randomized study showed.The findings, published in JAMA Surgery, revealed that early specialist palliative care for this group of patients, who underwent major abdominal operations to cure or control their cancer, did not produce a
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Gut microbiome may influence pancreatic cancer survival - 11 month(s) ago
Stool from long-term survivors of pancreatic adenocarcinoma had an increased relative abundance of the bacterial species Faecalibacterium prausnitzii and Akkermansia mucinophilia, according to data published in Cancer.Both species have previously been associated with immune response to cancer therapies, researchers noted.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results published in @JournalCancer provide new insights into the link between the gut microbiome and treatment response in pancreatic cancer. We spoke with @kharofaJ of @UCincyMedicine to learn more. https://t.co/Y1Eeq9M1rd #pancreaticcancer #OncAlert #MedEd #GITwitter
-
-
Mashup Score: 0Active surveillance viable for low-risk thyroid cancer - 12 month(s) ago
Active surveillance of newly diagnosed thyroid cancer appeared to be a viable alternative to surgery for certain patients with low-risk disease, results of a prospective trial published in JAMA Oncology showedPatients who underwent active surveillance also exhibited less anxiety — both at baseline and long term, according to investigators.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Active surveillance viable for low-risk thyroid cancer. https://t.co/qjrVBVFaMj #HeadNeckCancerAwarenessMonth #HeadNeckCancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 1Pembrolizumab plus chemoradiotherapy shows favorable EFS trend in head/neck cancer - 12 month(s) ago
The addition of pembrolizumab to chemoradiotherapy demonstrated a trend toward longer EFS among patients with locally advanced head and neck squamous cell carcinoma, according to data presented at ESMO Congress.Although the difference in EFS compared with placebo and chemoradiotherapy (CRT) did not achieve statistical significance, the results of the phase 3 KEYNOTE-412 study provide valuable
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Pembrolizumab plus chemoradiotherapy shows favorable EFS trend in head/neck cancer. https://t.co/SHnG3F55EA #HeadNeckCancerAwarenessMonth #HeadNeckCancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer - 12 month(s) ago
First-line treatment with zolbetuximab added to chemotherapy significantly extended OS and PFS among adults with certain forms of claudin-18.2-positive/HER2-negative gastric adenocarcinoma, results of the phase 3 SPOTLIGHT trial showed.Study participants, who had locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, demonstrated a 25% reduction in risk
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer. https://t.co/f6oZybULVQ #EsophagealCancerAwarenessMonth #EsophagealCancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Healthy diet may extend survival for patients with head and neck cancer - 12 month(s) ago
Patients with head and neck cancer who consumed a diet high in nutrients found to deter chronic disease had a 93% lower likelihood of death due to any cause during the first 3 years after diagnosis, according to study results.The findings, published in Frontiers in Nutrition, could be instrumental in the creation of future studies of dietary interventions and medical nutrition therapy guidelines
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Healthy diet may extend survival for patients with head and neck cancer. https://t.co/ZvA39MydLI #HeadNeckCancerAwarenessMonth #HeadNeckCancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
A nurse-created algorithm helped determine which patients with multiple myeloma exhibited the highest risk for pneumonia, according to study results.Cancer or its treatments can lead to low white blood cell counts.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Healio spoke with Carrie Bellerive, BSN, RN, BMTCN about an algorithm and the potential implications of the approach. https://t.co/YzvvWbBe0s @huntsmancancer #HemOnc #OncAlert #MedEd #multiplemyeloma #pneumonia #oncologynursing https://t.co/NWX57g1s0Q
-
-
Mashup Score: 0Pembrolizumab regimen extends survival in advanced gastric, gastroesophageal cancer - 12 month(s) ago
The addition of pembrolizumab to chemotherapy significantly extended survival among patients with advanced HER2-negative gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-859 study.The findings, presented during an ESMO Virtual Plenary session Thursday, also showed statistically significant and clinically meaningful improvements in PFS and overall response
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Pembrolizumab regimen extends survival in advanced gastric, gastroesophageal cancer. https://t.co/ugLFFqN59z #EsophagealCancerAwarenessMonth #EsophagealCancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup - 12 month(s) ago
Tislelizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS vs. chemotherapy alone among patients with PD-L1-positive, advanced gastric or gastroesophageal junction adenocarcinoma.The findings, presented at ASCO Gastrointestinal Cancers Symposium, additionally showed first-line treatment with tislelizumab (BGB-A317, BeiGene), a humanized
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup. https://t.co/GY6N4TomXa #EsophagealCancerAwarenessMonth #EsophagealCancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
Adding regorafenib to best supportive care significantly increased survival rates compared with placebo among patients with refractory advanced gastroesophageal cancer, results of the randomized, phase 3 INTEGRATE IIa trial showed. Data presented at ASCO Gastrointestinal Cancers Symposium confirmed the consistent survival benefit of regorafenib (Stivarga, Bayer) across regions and racial/ethnic
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Regorafenib extends survival in refractory advanced gastroesophageal cancer. https://t.co/mUNoHw3t3K #EsophagealCancerAwarenessMonth #EsophagealCancer #HemOnc #OncAlert #MedEd
-
Certain patients undergoing cancer surgery with curative intent derived no benefit from palliative care specialist services, data in @JAMASurgery showed. Healio spoke with @mcshinalljr of @VUMChealth to learn more. https://t.co/81lmR88NPz #OncAlert